SUN-112 Arcuate 11-Betahydroxysteroid Dehydrogenase Type1 Regulates Energy Homeostasis

Introduction: Despite the ongoing increase in the prevalence of obesity, there are few licensed anti-obesity medications, and these therapies have limited efficacy and significant side effects. Therefore, new treatments are being developed, including 11-βhydroxysteroid dehydrogenase type1 (11βHSD1)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Endocr Soc
Auteurs principaux: Izzi-Engbeaya, Chioma, Ma, Yue, Buckley, Niki, Ratnasabapathy, Risheka, Richardson, Errol, Counsell, John, Fernandes-Freitas, Isabel, Norton, Mariana, Farooq, Gala, Mirza, Zainab, Cheetham, Sharon, Seckl, Jonathan, Murphy, Kevin, Dhillo, Waljit, Gardiner, James
Format: Artigo
Langue:Inglês
Publié: Endocrine Society 2019
Sujets:
Adipose Tissue, Appetite, and Obesity
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552872/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-112
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires